|
Fortis Life Sciences
rabbit α kif18a ![]() Rabbit α Kif18a, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/bio_rxiv__64898__2026__05__21__726809-220-36-38 Average 93 stars, based on 1 article reviews
rabbit α kif18a - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Proteintech
rabbit polyclonal ace2 antibody ![]() Rabbit Polyclonal Ace2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/pm41796239-86-2-7 Average 93 stars, based on 1 article reviews
rabbit polyclonal ace2 antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Fortis Life Sciences
rabbit anti kif18a ![]() Rabbit Anti Kif18a, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/bio_rxiv__64898__2026__02__08__704347-211-11-14 Average 93 stars, based on 1 article reviews
rabbit anti kif18a - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Amgen
recombinant human kif18a ![]() Recombinant Human Kif18a, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/human+kif18a+recombinant/us12540129-890-0-18 Average 86 stars, based on 1 article reviews
recombinant human kif18a - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Insilico Medicine
kif18a novel inhibitors ![]() Kif18a Novel Inhibitors, supplied by Insilico Medicine, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/inhibitors+kif18a+novel/pm41543111-149-5-1 Average 86 stars, based on 1 article reviews
kif18a novel inhibitors - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Amgen
amgen volastra kif18a inhibitors ![]() Amgen Volastra Kif18a Inhibitors, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/human+kif18a+recombinant/pm41543111-175-3-3 Average 86 stars, based on 1 article reviews
amgen volastra kif18a inhibitors - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Bethyl
rabbit antibodies against kif18a ![]() Rabbit Antibodies Against Kif18a, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/pm41369352-86-34-39 Average 93 stars, based on 1 article reviews
rabbit antibodies against kif18a - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Fortis Life Sciences
rabbit antibodies against kif18a ![]() Rabbit Antibodies Against Kif18a, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/pmc12691420-82-34-39 Average 93 stars, based on 1 article reviews
rabbit antibodies against kif18a - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Bethyl
080a rrid ab 2296551 ![]() 080a Rrid Ab 2296551, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kif18a/KIF18A+Antibody/pmc12834474-6-6-4 Average 93 stars, based on 1 article reviews
080a rrid ab 2296551 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Representative images of RPE1- hTERT -iCas9 Δ TP53 (WT), RPE1- hTERT -iCas9 Δ TRIP13 Δ TP53 (Δ TRIP13 ), RPE1- hTERT -iCas9 Δ SKA2 Δ TRIP13 Δ TP53 (Δ SKA2 Δ TRIP13 ), and RPE1- hTERT -iCas9 Δ SKA3 Δ TRIP13 Δ TP53 (Δ SKA3 Δ TRIP13 ) cells stained with a live-cell DNA probe, undergoing division. Cell fates are color-coded: blue bars indicate completed mitosis, teal bars indicate an aberrant anaphase. An asterisk is placed to identify aberrancies. Time is indicated in hours:minutes. Scale bar, 10 μm. ( B ) Quantification of mitotic cell fates of WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ SKA3 Δ TRIP13 cells by live-cell imaging. For (B-E), 229, 221, 171, and 155 were analyzed for WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ SKA3 Δ TRIP13 cells, respectively. ( C ) Mitotic exit timing. Cells were tracked for more than 20 hours, but no new mitotic exits were observed after 6 hours. Only cells observed entering mitosis were included in this analysis. Shaded area indicates standard error. Data for WT and Δ TRIP13 are identical to those shown in Figure S1G. ( D ) Mitotic duration (measured as time from nuclear envelope breakdown (NEBD) to anaphase). Only cells observed entering and exiting mitosis were included in this analysis. ( E ) Time to metaphase alignment of WT, Δ TRIP13, Δ SKA2 Δ TRIP13 , and Δ SKA3 Δ TRIP13 cells. ( F ) Dose-response relative viability curve after treatment with varying concentrations of Noscapine. ( G ) Relative viability upon CRISPR-based gene knockout or chemical inhibition of KIF18A using Sovilnesib. Data in (B-G) were obtained from three biological independent experiments, for (F) and (G) with technical triplicates. Statistical significance was assessed by Fisher’s exact test (B), log-rank test (C), or two-way ANOVA (D-E) and (G), each with correction for multiple comparisons. *P<0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: Staining, Live Cell Imaging, CRISPR, Gene Knockout, Inhibition
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Volcano plot showing mitosis-linked genes whose loss causes synthetic viability (SV) in RPE1- hTERT -iCas9 Δ TRIP13 Δ TP53 (Δ TRIP13 ) cells relative to RPE1- hTERT -iCas9 Δ TP53 (WT) cells in the CRISPR screen. Significant hits (FDR < 0.1) are shown in dark gray. ( B ) Volcano plots showing gene co-dependency correlations with KIF18A across cancer cell lines. The x-axis represents the Pearson correlation coefficient (r), the y-axis shows the significance. Genes with significant co-dependency (q < 0.05) are shown in dark gray. ( C ) Schematic depicting SAC-contingent synthetic viable factors and the rationale for the Δ SKA1 Δ TRIP13 versus Δ TRIP13 setup to derive epistatic relationships. ( D ) Comparison of gene effects in the Δ TRIP13 and Δ SKA1 Δ TRIP13 CRISPR screens based on the mean abundance scores of four sgRNAs per gene. Plotted genes were significant synthetic viable hits in the Δ TRIP13 screen (positive fold change in guide abundance). Significance is assessed through one-way ANOVA with correction for multiple comparisons, by comparison to the mean of SKA1-3 and KIF18A guide abundances in the Δ SKA1 Δ TRIP13 screen. ( E and F ) Relative viability upon CRISPR-based gene knockout or chemical inhibition. n = 2-4 biologically independent experiments with technical triplicates. Two-way ANOVA with correction for multiple comparisons, **P < 0.01; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: CRISPR, Comparison, Gene Knockout, Inhibition
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: Volcano plots showing gene co-dependency correlations with SKA1 , SKA2 and SKA3 across cancer cell lines, ( A ) specifically focused on the SKAc, KIF18A, and Augmin complex or ( B ) specifically focused on the other mitosis-linked synthetic viable hits identified in the CRISPR screen. The x-axis represents the Pearson correlation coefficient (r), the y-axis shows the significance. Genes with significant co-dependency (q < 0.05) are shown in dark gray. ( C ) Volcano plots showing gene co-dependency correlations with HAUS1-8 across cancer cell lines, specifically focused on the SKAc, KIF18A, and the Augmin complex. The x-axis represents the Pearson correlation coefficient (r), the y-axis shows the significance. Genes with significant co-dependency (q < 0.05) are shown in dark gray
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: CRISPR
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Schematic overview of the genome-wide Δ TRIP13 versus Δ SKA1 Δ TRIP13 CRISPR-Cas9 knockout screen workflow performed in triplicate. Dox, doxycycline; NGS, next-generation sequencing. ( B ) Relative viability of RPE1- hTERT -iCas9 Δ TP53 (WT), RPE1- hTERT -iCas9 Δ TRIP13 Δ TP53 (Δ TRIP13 ), RPE1-hTERT-iCas9 Δ SKA2 Δ TRIP13 Δ TP53 ( Δ SKA2 Δ TRIP13), and RPE1-hTERT-iCas9 Δ KIF18A Δ TRIP13 Δ TP53 ( Δ KIF18A Δ TRIP13) cells upon CRISPR-based gene knockout. ( C ) Representative western blot of TRIP13 and KIF18A in WT, Δ TRIP13 , and Δ KIF18A Δ TRIP13 cells. ( D ) Relative viability upon CRISPR-based gene knockout. Data in (B) and (D) were obtained from three biologically independent experiments with technical triplicates. Statistical significance was assessed by two-way ANOVA with correction for multiple comparisons. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: Genome Wide, CRISPR, Knock-Out, Next-Generation Sequencing, Gene Knockout, Western Blot
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Sensitivity of near-euploid and highly aneuploid cancer cell lines to loss of KIF18A (left), SKA1 (middle), or SKA1-3 (right), as measured in the Chronos CRISPR-Cas9 dataset. More negative dependency scores indicate greater gene essentiality. ( B ) Representative western blot of KIF18A, TRIP13, SKA1, and SKA2 across a panel of cancer cell lines with differing sensitivity to KIF18A inhibition. ( C ) Relative viability of cancer cell lines with differing sensitivity to KIF18A inhibition after treatment with 155 nM Sovilnesib, a KIF18A inhibitor. ( D ) Percentage of pH3-positive mitotic cells measured by flow cytometry after treatment with mock or SKA2 siRNA for 60 hours. Grouped as KIF18A-inhibition-insensitive (HCT-116, DLD-1) and KIF18A-inhibition-sensitive (HCC-1806, HeLa, OVCAR-3). Statistical comparison between groups are based on mitotic fraction upon si SKA2 treatment. ( E ) Relative viability after SKA2 depletion, grouped as KIF18A-inhibition-insensitive (HCT-116, DLD-1) and KIF18A-inhibition-sensitive (HCC-1806, HeLa, OVCAR-3). Data in (C) and (E) were obtained from three or four biologically independent experiments with technical triplicates, and data in (D) were obtained from two or five biologically independent experiments with technical duplicates. Statistical significance was assessed by two-tailed unpaired t-test (A), nested two-tailed t-test (C and E), two-way ANOVA with correction for multiple comparisons (D), and nested t-test (D). *P < 0.05; **P < 0.01; ***P = 0.0002; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: CRISPR, Western Blot, Inhibition, Flow Cytometry, Comparison, Two Tailed Test
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) The correlation between aneuploidy scores and the dependency on ( A ) SKA complex genes, ( B ) KIF18A, ( C ) Augmin complex genes, ( D ) mitosis-linked identified synthetic viable hits, in the Chronos CRISPR-Cas9 dataset. Pearson correlation coefficient and corresponding P value are indicated.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: CRISPR
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Dose-response relative viability curve after treatment with varying concentrations of the KIF18A inhibitor Sovilnesib. Results obtained for the concentration of 155 nM, indicated with the dashed lines, are also shown in . ( B ) Western blot of SKA2 levels after treatment with mock or SKA2 siRNA. ( C ) Cell growth curve of unperturbed cancer cell lines, based on fold changes in cell counts over time. ( D ) Percentage of phospho-Histone H3-ser10 positive mitotic cells measured by flow cytometry after treatment with mock or CSNK1A1, CUL3, PPP1R12A, MAGOH, PPP1CB, or SKA2 siRNA for 60 hours. ( E ) Relative viability after protein depletion, grouped as KIF18A-inhibition-insensitive (HCT-116, DLD-1) and KIF18A-inhibition-sensitive (HCC-1806, HeLa, OVCAR-3). Data were obtained in three (A) and (C), two (D), or four (E) biologically independent experiments with technical triplicates (A), (C), (E) or duplicates (D). Statistical significance was assessed by two-way ANOVA with correction for multiple comparisons. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: Concentration Assay, Western Blot, Flow Cytometry, Inhibition
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: (A ) Representative images of RPE1- hTERT -iCas9 Δ TP53 (WT), RPE1- hTERT -iCas9 Δ TRIP13 Δ TP53 (Δ TRIP13 ), RPE1- hTERT -iCas9 Δ SKA2 Δ TRIP13 Δ TP53 (Δ SKA2 Δ TRIP13 ), and RPE1- hTERT -iCas9 Δ KIF18A Δ TRIP13 Δ TP53 (Δ KIF18A Δ TRIP13 ) cells stained for CREST (magenta), KIF18A (black), and SKA3 (cyan). Scale bar, 5 μm. ( B ) Spindle length of WT, ΔTRIP13 , ΔSKA2ΔTRIP13 , and ΔKIF18AΔTRIP13 cells, with or without MG-132 or Sovilnesib treatment. For WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 49, 54, 40, and 47 cells were analyzed, respectively. For MG-132-treated WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 45, 30, 38, and 46 cells were analyzed, respectively. For Sovilnesib-treated WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13 , 49, 47 and 36 cells were analyzed, respectively. ( C ) Maximum metaphase plate spread of WT, ΔTRIP13 , ΔSKA2ΔTRIP13 , and ΔKIF18AΔTRIP13 cells, with or without MG-132 or Sovilnesib treatment. For WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 49, 53, 40, and 48 cells were analyzed, respectively. For MG-132-treated WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 45, 30, 38, and 46 cells were analyzed, respectively. For Sovilnesib-treated WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13 , 52, 49, and 36 cells were analyzed, respectively. ( D ) Dose-response curve of relative viability after treatment with varying concentrations of ProTAME, and relative viability upon 2.75 μM of ProTAME. The concentration of 2 μM, indicated with the dashed lines, was used for subsequent experiments. ( E ) Representative images of Δ SKA2 Δ TRIP13 cells stained with a live-cell DNA probe, undergoing division after treatment with 2 μM ProTAME. Teal bars indicate aberrant anaphase. An asterisk is placed to identify aberrancies. Time is indicated in hours:minutes. Scale bar, 10 μm. ( F ) Quantification of mitotic cell fates by live-cell imaging after treatment with 2 µM ProTAME. 194, 281, and 186 cells were analyzed for WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13 cells, respectively. ( G ) A model depicting the identification of the SKAc as a KIF18A-like mitotic vulnerability of chromosomally unstable cancers, influenced by mitotic duration. SKAc and KIF18A impact chromosome alignment through distinct mechanisms. Data in (B) and (C) were obtained from three or four biologically independent experiments, data in (D-F) were obtained from three biologically independent experiments, with technical triplicates in (D). Statistical significance was assessed by two-way ANOVA with correction for multiple comparisons (B-D), and pairwise Fisher’s exact test with correction for multiple comparisons (F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: Staining, Concentration Assay, Live Cell Imaging
Journal: bioRxiv
Article Title: The SKA complex is a mitotic vulnerability of chromosomally unstable cancers
doi: 10.64898/2026.05.21.726809
Figure Lengend Snippet: ( A ) Full width at half maximum (FWHM) of the metaphase plate of RPE1- hTERT -iCas9-Δ TP53 (WT), RPE1- hTERT -iCas9 Δ TP53 Δ TRIP13 (Δ TRIP13 ), RPE1- hTERT -iCas9 Δ TP53 Δ SKA2 Δ TRIP13 (Δ SKA2 Δ TRIP13 ), and RPE1- hTERT -iCas9 Δ TP53 Δ KIF18A Δ TRIP13 (Δ KIF18A Δ TRIP13 ) cells, with or without MG-132 or Sovilnesib treatment. For WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 48, 50, 40, and 48 cells were analyzed, respectively. For MG-132-treated WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 , 45, 30, 38, and 46 cells were analyzed, respectively. For Sovilnesib-treated WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13, 52, 49, and 36 cells were analyzed, respectively. ( B ) Representative images of WT, Δ TRIP13 , Δ SKA2 Δ TRIP13 , and Δ KIF18A Δ TRIP13 cells treated with 5 μM MG-132 or 250 nM Sovilnesib, treatments used in -D and Fig. S10B. ( C ) Schematic overview of the live-cell imaging workflow used to image the first mitosis after ProTAME treatment. ( D ) Mitotic duration (measured as time from NEBD to anaphase) of WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13 cells treated with 2 µM ProTAME. Average duration per condition: WT = 40 minutes, Δ TRIP13 = 68 minutes, Δ SKA2 Δ TRIP13 = 59 minutes. Only cells observed entering and exiting mitosis were included in this analysis. 194, 281, and 186 cells were analyzed for WT, Δ TRIP13 , and Δ SKA2 Δ TRIP13 cells, respectively. Data in (A) were obtained in three or four biologically independent experiments, data in (C) were obtained in three biologically independent experiments. Statistical significance was assessed by two-way ANOVA (A) and one-way ANOVA (C), each with correction for multiple comparisons. *P = 0.03; ****P < 0.0001; ns, not significant.
Article Snippet: After blocking in 5% milk in TBS-T for 30 minutes, membranes were incubated at 4°C overnight with the following primary antibodies at the indicated dilutions in 5% milk in TBS-T: mouse α-HSP90 α/β (Biolegend 675402, 1:9000),
Techniques: Live Cell Imaging
Journal: Cells
Article Title: The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells
doi: 10.3390/cells14231863
Figure Lengend Snippet: Impact of ATX020 on KIF18A motor function. ( A ) Immunofluorescence images of cells stained for KIF18A (red), α-tubulin (green), and nuclear stain DAPI (blue). Cells were untreated or treated with ATX020 (1 µM for A2780; 0.5 µM for OVCAR3 and OVCAR8) for 48 h before staining with the respective antibodies. ( B ) Spindle length (distance between spindle poles) was quantified in ≥ 25 metaphase cells per condition using FIJI™. Data are shown as mean ± SD ( n = 3). Significance between treatments was analyzed by unpaired t -test (** p < 0.01; *** p < 0.001).
Article Snippet: Next, the slides were blocked in a blocking buffer (composed of 2.5% FBS, 200 mM glycine, and 0.1% Triton X-100 in PBS) for 1 h. They were then incubated in a blocking buffer containing
Techniques: Immunofluorescence, Staining